Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA(1c) in New-Onset Type 1 Diabetes

OBJECTIVE: A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that 1) low-dose ATG/GCSF or 2)...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Diabetes Care
Main Authors: Haller, Michael J., Schatz, Desmond A., Skyler, Jay S., Krischer, Jeffrey P., Bundy, Brian N., Miller, Jessica L., Atkinson, Mark A., Becker, Dorothy J., Baidal, David, DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Herold, Kevan C., Marks, Jennifer B., Moran, Antoinette, Rodriguez, Henry, Russell, William, Wilson, Darrell M., Greenbaum, Carla J.
Formáid: Artigo
Teanga:Inglês
Foilsithe: American Diabetes Association 2018
Ábhair:
Emerging Therapies: Drugs and Regimens
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105329/
https://ncbi.nlm.nih.gov/pubmed/30012675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc18-0494
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla